Loading...
LGRNX | RGACX | LGRNX / RGACX | |
Total Expense Ratio | 0.57 | 0.94 | 61% |
Annual Report Gross Expense Ratio | 0.57 | 0.94 | 61% |
Fund Existence | 11 years | 22 years | - |
Gain YTD | 45.153 | 30.139 | 150% |
Front Load | N/A | N/A | - |
Min. Initial Investment | 1000000 | 250 | 400,000% |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 12B | 214B | 6% |
Annual Yield % from dividends | 0.00 | 0.00 | - |
Returns for 1 year | 19.49 | 20.71 | 94% |
Returns for 3 years | -1.13 | -3.02 | 37% |
Returns for 5 years | 54.04 | 33.53 | 161% |
Returns for 10 years | 180.42 | 118.43 | 152% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
CFCV | 34.53 | 0.09 | +0.26% |
Clearbridge Focus Value ESG ETF | |||
OCTW | 32.33 | 0.06 | +0.17% |
AllianzIM US Large Cap Buffer20 Oct ETF | |||
AOR | 51.83 | N/A | N/A |
iShares Core Growth Allocation ETF | |||
HQL | 12.44 | N/A | N/A |
abrdn Life Sciences Investors | |||
IBHH | 22.81 | -0.06 | -0.26% |
iShares iBonds 2028 Term HY & Inc ETF |